newsfilter
← Latest News
PR Newswire·

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BIOA
  • BioArctic's partner Eisai published a simulation projecting Leqembi sales of approximately JPY 300 billion (SEK 17.6 billion) for fiscal year 2028 ending March 2029.
  • The simulation was disclosed on May 25, 2026, as required by the EU Market Abuse Regulation.
  • Leqembi is approved in 53 countries with regulatory reviews ongoing in 6 additional countries.
  • Intravenous maintenance dosing every four weeks is approved in 7 countries including the US, UK, China, & Japan.
  • In the US, Leqembi Iqlik is approved for subcutaneous maintenance dosing using an autoinjector.
  • A new drug application for a subcutaneous formulation was submitted in Japan in November 2025.
  • Leqembi was added to China's 'Commercial Insurance Innovative Drug List' in December 2025.
  • The US FDA granted Priority Review in January 2026 for a supplemental application regarding a subcutaneous starting dose, with a PDUFA date set for August 24, 2026.
  • The subcutaneous formulation application was accepted for priority review in China in February 2026.
  • The Phase 3 AHEAD 3-45 clinical study for preclinical Alzheimer's disease is ongoing after fully recruiting in October 2024.
  • The Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease is ongoing with lecanemab as the backbone therapy.
  • BioArctic maintains a long-term collaboration with Eisai since 2005 for Alzheimer's drug development & commercialization.
  • BioArctic holds rights to commercialize lecanemab in the Nordic region & receives payments based on sales milestones & royalties.
  • BioArctic is a Swedish biopharma company listed on Nasdaq Stockholm focused on neurodegenerative disease treatments.
  • BioArctic utilizes its proprietary BrainTransporter™ technology to transport antibodies across the blood-brain barrier.